Targets › TEC
2 programs from 2 companies in 19 trials: 10 Phase 3, 9 Phase 2; Immunology, Metabolic and endocrine; next expected readout Dec 2026.
Non-receptor tyrosine kinase that contributes to signaling from many receptors and participates as a signal transducer in multiple downstream pathways, including regulation of the actin cytoskeleton. Plays a redundant role to ITK in regulation of the adaptive immune response. (UniProt, P42680)
Open in Phaseline: the race on TEC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | Ritlecitinib Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor | JAK3, ITK, BMX, TEC, TXK | Phase 3 | Severe Alopecia Areata; Vitiligo; Stable Nonsegmental Vitiligo; Alopecia Areata … | Dec 2026 |
| Takeda | Zasocitinib TEC kinase inhibitor | TEC, ZAP70 | Phase 3 | Psoriatic Arthritis; Plaque Psoriasis; Hidradenitis Suppurativa; Nonsegmental Vitiligo … | Feb 2027 |
Psoriatic Arthritis (3) Hidradenitis Suppurativa (2) Crohn's Disease (2) Severe Alopecia Areata (2) Vitiligo (2) Alopecia Areata (2) Plaque Psoriasis (1) Nonsegmental Vitiligo (1) Stable Nonsegmental Vitiligo (1) Chronic Spontaneous Urticaria (1) Keloid (1) Diabetes Mellitus, Type 1 (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.